PCRX - Pacira BioSciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.186B

Cash

325.9M

Avg Qtr Burn

N/A

Short % of Float

14.12%

Insider Ownership

1.58%

Institutional Own.

-

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZILRETTA® (triamcinolone acetonide) Details Osteoarthritis Knee Pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exparel (bupivacaine liposome) Details Post operative acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exparel (bupivacaine liposome) Details Post operative acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PCRX-201 (FX201) (humantakinogene hadenovec) Details Osteoarthritis pain	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PCRX-301 (FX301) (NaV1.7 inhibitor) Details Post operative acute pain , Pain	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.